Quintiles Transitional Holdings Inc. (Q) Upgraded to Buy at Zacks Investment Research
Quintiles Transitional Holdings Inc. (NYSE:Q) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The brokerage currently has a $107.00 target price on the medical research company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 11.23% from the company’s current price.
According to Zacks, “Quintiles Transnational Holdings Inc. provides professional services, information and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries. The Company has two segments: Product Development and Integrated Healthcare Services. It offers project management, clinical monitoring services, strategic planning and design services, consulting services contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, brand and scientific communication, and medical education services; outcome/observational services. The Company operates in Americas, Europe and Africa, and the Asia-Pacific. Quintiles Transnational Holdings Inc. is based in Durham, North Carolina. “
A number of other equities research analysts also recently weighed in on the stock. Citigroup Inc. reaffirmed a “neutral” rating and issued a $96.00 target price (up from $87.00) on shares of Quintiles Transitional Holdings in a research note on Wednesday, June 28th. Robert W. Baird raised shares of Quintiles Transitional Holdings from an “underperform” rating to a “neutral” rating and raised their target price for the company from $76.00 to $93.00 in a research note on Friday, July 7th. Barclays PLC reaffirmed an “overweight” rating and issued a $98.00 target price (up from $90.00) on shares of Quintiles Transitional Holdings in a research note on Monday, July 17th. Argus raised their target price on shares of Quintiles Transitional Holdings from $98.00 to $104.00 and gave the company a “buy” rating in a research note on Monday, September 18th. Finally, Royal Bank Of Canada began coverage on shares of Quintiles Transitional Holdings in a research note on Tuesday, September 19th. They issued an “outperform” rating and a $116.00 target price on the stock. Ten equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $93.61.
Quintiles Transitional Holdings (NYSE:Q) opened at 96.20 on Wednesday. The firm has a market capitalization of $20.83 billion, a PE ratio of 278.84 and a beta of 0.62. Quintiles Transitional Holdings has a 12 month low of $70.10 and a 12 month high of $99.95. The stock has a 50 day moving average of $95.61 and a 200 day moving average of $88.58.
Quintiles Transitional Holdings (NYSE:Q) last announced its earnings results on Thursday, August 3rd. The medical research company reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.04. The business had revenue of $1.97 billion for the quarter, compared to the consensus estimate of $1.96 billion. Quintiles Transitional Holdings had a net margin of 0.82% and a return on equity of 14.23%. Quintiles Transitional Holdings’s quarterly revenue was up 68.7% on a year-over-year basis. During the same period last year, the firm posted $0.93 earnings per share. On average, equities analysts predict that Quintiles Transitional Holdings will post $4.58 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Quintiles Transitional Holdings Inc. (Q) Upgraded to Buy at Zacks Investment Research” was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/11/quintiles-transitional-holdings-inc-q-upgraded-to-buy-at-zacks-investment-research.html.
In related news, insider Ari Bousbib sold 92,160 shares of Quintiles Transitional Holdings stock in a transaction on Monday, August 7th. The shares were sold at an average price of $90.35, for a total value of $8,326,656.00. Following the transaction, the insider now directly owns 1,082,919 shares of the company’s stock, valued at $97,841,731.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin C. Knightly sold 20,000 shares of Quintiles Transitional Holdings stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $90.28, for a total transaction of $1,805,600.00. Following the completion of the transaction, the insider now directly owns 46,826 shares in the company, valued at $4,227,451.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,198,382 shares of company stock worth $1,361,834,375. 6.40% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of Q. UBS Asset Management Americas Inc. increased its stake in shares of Quintiles Transitional Holdings by 4.7% in the first quarter. UBS Asset Management Americas Inc. now owns 400,657 shares of the medical research company’s stock worth $32,265,000 after buying an additional 18,040 shares during the period. Prudential Financial Inc. boosted its holdings in Quintiles Transitional Holdings by 24.6% in the first quarter. Prudential Financial Inc. now owns 18,721 shares of the medical research company’s stock valued at $1,508,000 after acquiring an additional 3,700 shares in the last quarter. FMR LLC boosted its holdings in Quintiles Transitional Holdings by 11.2% in the first quarter. FMR LLC now owns 215,936 shares of the medical research company’s stock valued at $17,389,000 after acquiring an additional 21,742 shares in the last quarter. Teachers Advisors LLC boosted its holdings in Quintiles Transitional Holdings by 23.6% in the first quarter. Teachers Advisors LLC now owns 381,161 shares of the medical research company’s stock valued at $30,695,000 after acquiring an additional 72,728 shares in the last quarter. Finally, Global X Management Co. LLC boosted its holdings in Quintiles Transitional Holdings by 30.8% in the first quarter. Global X Management Co. LLC now owns 1,469 shares of the medical research company’s stock valued at $118,000 after acquiring an additional 346 shares in the last quarter. 93.21% of the stock is currently owned by institutional investors.
Quintiles Transitional Holdings Company Profile
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.